ELV and UNH stand out as two of the biggest players in U.S. managed care, and their performance often serves as a useful signal for the wider health-insurance group. This comparison is especially relevant for investors tracking defensive large-cap exposure, value opportunities, or how insurers are navigating medical-cost trends and government-program challenges. Because the companies operate in the same macro setting but follow different business models, looking at their recent momentum, margin paths, and positioning can help clarify where the sector may be headed.
ELV, or Elevance Health, Inc., runs one of the largest health-benefits operations in the country, serving roughly 45 million medical members across commercial, Medicare, Medicaid, and federal programs. It also manages the CarelonRx pharmacy and Carelon Services businesses. The stock has traded well above its 52-week low lately, helped by the broader managed-care recovery and better sentiment toward the group. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Elevance’s most recent quarterly results beat consensus estimates, although year-over-year earnings declined amid higher medical costs in Medicaid. Management raised its full-year adjusted EPS outlook and kept its target of at least 12% EPS growth in 2027, describing 2026 as a trough year for Medicaid margins. Sentiment reflects disciplined membership adjustments, cost controls, and growth in Carelon’s services, even as membership declines and regulatory questions remain on the radar.
UNH, UnitedHealth Group Incorporated, is the largest U.S. health insurer. It combines the UnitedHealthcare insurance operations with Optum, its platform covering clinical care, technology, and pharmacy benefit management. The stock has recovered sharply from its lows in recent months as investors have grown more confident in the company’s turnaround.
UnitedHealth’s latest quarterly report beat Wall Street expectations, with adjusted EPS rising year over year and the medical cost ratio improving to 88.4% from 89.9% a year earlier. Management raised its full-year adjusted EPS guidance for the third time this year, pointing to better plan design, pricing discipline, and cost controls. These improvements have been partly offset by exits from unprofitable products and notable Medicare Advantage membership losses, yet the margin and earnings trends have clearly strengthened.
The companies stand apart most clearly in their growth drivers and margin profiles. UnitedHealth’s Optum delivers diversified, non-insurance revenue across care delivery, data analytics, and pharmacy services, which has historically supported more stable margins. Elevance’s Carelon serves a similar purpose but on a smaller scale, leaving the company more reliant on its core Health Benefits segment.
On recent momentum, UNH has posted steadier quarter-over-quarter margin gains, with its medical cost ratio moving in the right direction and guidance lifted multiple times. ELV is still addressing Medicaid cost pressures and sees those margins bottoming in 2026, although it has laid out a clearer route to 2027 earnings growth. On valuation, ELV generally trades at a lower price-to-earnings multiple, reflecting its greater exposure to government-program uncertainty, while UNH carries a premium for its scale and diversification. Key risks for both include medical-cost inflation, Medicare Advantage regulation, and PBM scrutiny, but Elevance’s concentrated Medicaid exposure and UnitedHealth’s larger Medicare Advantage membership losses create different trade-offs to consider.
Based on the observable factors, the data-driven view leans toward UnitedHealth in the current environment. UNH has shown more consistent trend improvement, including a declining medical cost ratio, three straight guidance increases, and firmer margin recovery across its insurance and Optum segments. Elevance offers a more attractive valuation and a credible 2027 growth story, but its near-term earnings remain more tied to a Medicaid margin recovery that is still in progress. The preference is probabilistic rather than absolute: UNH currently appears to combine stronger trend consistency, stability, and positive catalysts, while ELV presents a higher-upside but less certain recovery path for those with a longer horizon.
In my own analysis of names like these, I sometimes review Tickeron’s AI Trading Bots to see how automated strategies are performing across similar healthcare stocks. The platform lets users examine different bot styles, timeframes, and risk levels that align with current market conditions, which can add another layer of perspective when evaluating relative opportunities.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
It is expected that a price bounce should occur soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 187 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
UNH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UNH as a result. In 56 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for UNH turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 27 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.
UNH moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for UNH crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
The Aroon Indicator for UNH entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.594) is normal, around the industry mean (3.520). P/E Ratio (25.266) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.024) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of hospital and medical service plans
Industry ManagedHealthCare